Food and Drug Administration Revitalization Act

[AI summary unavailable — showing source text] Prescription Drug User Fee Amendments of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to make changes to provisions governing prescription drug user fees. Removes provisions limiting the postmarket safety activities on approved human drug applications to three years after approval of a new drug. Sets forth provisions regarding user fees for human drug applications and supplements that the Secretary of Health and Human Services must collect beginning in FY2008, including the amount of revenue that such fees are to generate and relevant adjustments to such fees. Requires the Secretary to assess and collect fees for advisory review by the Secretary of direct-to-consumer television advertisements for a prescription drug product. Sets forth procedures for such review. Subjects each person that is assessed an advisory review fee to an operating reserve fee for the first fiscal year in which an advisory review fee is assessed. Requires the Secretary to: (1) annually set the fee for advisory review based on the number of direct-to-consumer advertisements that the Secretary will review in the next fiscal year; and (2) establish a Direct-to-Consumer Advisory Review Operating Reserv…